
|Videos|September 9, 2022
Use of PARP Inhibitors in Breast Cancer: Implications for Pharmacy Practice
About 1 in 8 women in the United States will develop breast cancer in their lifetime. Overall mortality for breast cancer has decreased over the years with the addition of complex treatment, such as PARP inhibitors. The webcast discusses this class of medications and see how they fit into the treatment paradigm for breast cancer.
Advertisement
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
3
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5

























